Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability
 of sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination (FDC) in participants with
 chronic hepatitis C virus (HCV) who have received a liver transplant.
Key Inclusion Criteria:

 -  History of chronic HCV infection (≥ 6 months)

 -  HCV genotype 1, 2, 3, 4, 5, 6, or indeterminate

 -  Liver transplant ≥ 3 months prior to screening

 -  Male and nonpregnant/ non-lactating female individuals without cirrhosis or with
 compensated cirrhosis

 Key Exclusion Criteria:

 -  History of clinically significant illness or any other medical disorder that may
 interfere with individual's treatment, assessment or compliance with the protocol,

 -  Co-infection with HIV or hepatitis B virus

 -  Known hypersensitivity to study medication,

 -  Use of any prohibited concomitant medications as within with window before the Day 1
 visit.

 -  De novo or recurrent hepatocellular carcinoma posttransplant

 NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.